A number of other research analysts also recently weighed in on MTEM. Zacks Investment Research downgraded Molecular Templates from a hold rating to a sell rating in a research note on Friday, August 16th. Cowen reissued a buy rating on shares of Molecular Templates in a research note on Wednesday, November 13th. TheStreet downgraded Molecular Templates from a c- rating to a d rating in a research note on Monday, August 5th. Finally, ValuEngine downgraded Molecular Templates from a sell rating to a strong sell rating in a research note on Wednesday, October 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Molecular Templates currently has a consensus rating of Hold and an average price target of $12.70.
Shares of MTEM stock traded down $0.22 during trading hours on Friday, reaching $7.04. The company had a trading volume of 10,618 shares, compared to its average volume of 209,781. The company has a 50 day moving average of $7.72 and a 200 day moving average of $7.04. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.66 and a quick ratio of 3.11. The firm has a market cap of $258.78 million, a price-to-earnings ratio of -6.90 and a beta of 2.99. Molecular Templates has a 1-year low of $3.19 and a 1-year high of $9.77.
Molecular Templates Company Profile
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.